cardiomedex
Cardiomedex is a France-based preclinical CRO founded in 2011, providing contract research services for cardiovascular and cardiometabolic drug development. It serves global pharmaceutical and biotechnology clients with proprietary animal models, functional exploration platforms, ex vivo assays, and drug-repositioning consulting.
- Company typePrivate
- Founded2011
- HeadquartersEscalquens, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What cardiomedex does
Cardiomedex is a French preclinical contract research organization (CRO) founded in 2011 by Dr. Thierry Sulpice and headquartered in Escalquens, near Toulouse, France. The company provides specialized research services for cardiovascular diseases and cardiometabolic complications, serving pharmaceutical and biotechnology clients globally. It operates as a subsidiary of Physiogenex, with which it shares facilities and scientific leadership, enabling an integrated operational backbone across cardiometabolic, metabolic, and renal disease research.
The company's core services are organized into four pillars: (1) in vivo disease models covering heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), myocardial infarction, cardiac hypertrophy, hypertension, and anthracycline-induced cardiotoxicity; (2) in vivo functional exploration using echocardiography, radiotelemetry, and Millar catheter probes for hemodynamic assessment; (3) ex vivo and in vitro assays including myograph and Langendorff isolated-heart preparations; and (4) consulting services for drug development and repositioning. Proprietary, validated disease models — notably a diet-induced NASH-HFpEF hamster model and the SDT fatty rat model for diabetic nephropathy — differentiate Cardiomedex's offering in the translational cardiovascular research market, where HFpEF and NASH-cardiac comorbidity have become high-priority indications for large-pharma pipelines.
Cardiomedex operates a project-based business model with custom-quoted, multi-year study contracts negotiated directly with client R&D teams, supplemented by consulting engagements. The company has no disclosed external funding and remains privately held. Customer acquisition is driven by direct sales, participation in major cardiology and metabolism conferences (AHA, ISHR, ISN, Keystone), peer-reviewed publications, and distribution partnerships such as the 2023 CLEA Japan agreement for the SDT fatty rat model. Cardiomedex also holds French Research Tax Credit (CIR) accreditation and operates in compliance with EU Directive 2010/63/EU for laboratory animal welfare, providing baseline eligibility for European preclinical outsourcing engagements.
cardiomedex firmographics
Firmographics- Name
- cardiomedex
- Legal name
- Cardiomedex SAS
- Website
- https://cardiomedex.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cardiomedex is a France-based preclinical CRO founded in 2011, providing contract research services for cardiovascular and cardiometabolic drug development. It serves global pharmaceutical and biotechnology clients with proprietary animal models, functional exploration platforms, ex vivo assays, and drug-repositioning consulting.
- Ownership category
- akta.pro rank
cardiomedex industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), General Cardiology (Consultative) (HLAKABAA)
Keywords
Where cardiomedex is headquartered
LocationHeadquarters
- HQ city
- Escalquens
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
cardiomedex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Preclinical CRO Services: Contract research organization providing fee-for-service preclinical studies for pharmaceutical and biotechnology companies evaluating cardiovascular drug candidates. Services include in vivo models, ex vivo/in vitro assays, and pharmacological characterization.
- Consulting Services: Strategy consulting services including research strategy development, study design and protocol development, literature research, medical writing, and strategic portfolio reviews for drug development and repositioning.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CRO service packages tailored to client specifications |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
cardiomedex product offering
Product offeringCore offering
Cardiomedex is a preclinical contract research organization (CRO) that provides fee-for-service preclinical studies for pharmaceutical and biotechnology companies developing cardiovascular and cardiometabolic drugs. Its offering combines three service lines: in vivo animal models (HFpEF, HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, NASH, diabetic nephropathy), in vivo functional exploration (echocardiography, telemetry, hemodynamic measurements), and ex vivo/in vitro assays (vascular reactivity, Langendorff perfused heart), supplemented by drug development consulting.
Product overview
Cardiomedex is a preclinical Contract Research Organization (CRO) highly specialized in cardiovascular diseases and cardiometabolic complications. The company operates as a unified platform combining three interconnected service lines: In Vivo Models (pathophysiological animal models including HFpEF/HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, and cardiometabolic models), In Vivo Exploration Platform (functional characterization via echocardiography, telemetry, hemodynamic measurements, and exercise testing), and Ex Vivo/In Vitro Assays (isolated organ studies and cellular assays). These core offerings are supplemented by personalized Consulting Services for drug development strategy, repositioning, and lifecycle management. Together, these services enable pharmaceutical and biotechnology companies to evaluate cardiac efficacy and safety of compounds using gold-standard and tailor-made experiments.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Successfully developed and validated NASH-HFpEF hamster model presented at AHA 2023 and ISHR 2023 conferences
- +1 more outcomes
Companies that use cardiomedex
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
cardiomedex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
cardiomedex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- CLEA Japan Inc.minorCollaborative partnership with CLEA Japan Inc. for the SDT fatty rat model development. CLEA Japan provides the SDT fatty rat model expertise and business development support. Presented collaborative work at ISN-World Congress of Nephrology in Bangkok, Thailand in March-April 2023.
- PhysiogenexcorePhysiogenex is a preclinical CRO specialized in metabolic disorders based in Toulouse, France with 15+ years of expertise. Cardiomedex and Physiogenex share the same CEO (Dr. Thierry Sulpice) and facilities. Together they provide an integrated approach to cardiometabolic diseases, enabling large-scale studies evaluating drug candidates on both cardiac and metabolic functions. Cardiomedex is a subsidiary company of Physiogenex.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
cardiomedex competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Large European-based CRO with extensive preclinical and clinical service lines, including cardiovascular safety pharmacology. Competes broadly for preclinical cardiovascular contracts across pharma sponsors.
- Crown Bioscience: Global preclinical CRO with cardiovascular and metabolic disease models, including translational platforms for HFpEF, diabetes, and NASH. Competes with Cardiomedex on specialized cardiometabolic preclinical studies with greater geographic footprint.
- WuXi AppTec: Asia-based global CRO/CDMO with preclinical capabilities including cardiovascular and metabolic disease models. Competes on scale, integrated offerings, and cost for outsourced preclinical studies.
- Charles River Laboratories: Global preclinical CRO with cardiovascular safety and efficacy capabilities across multiple species and therapeutic areas. Broad incumbent that competes with Cardiomedex on large cardiovascular preclinical programs but at vastly greater scale.
- Inotiv: US-based preclinical CRO with cardiovascular safety pharmacology, toxicology, and disease model capabilities. Competitor for North American sponsor preclinical cardiovascular programs.
- Medpace: Mid-sized CRO with strong cardiovascular therapeutic area presence, primarily clinical but with preclinical-adjacent relationships. Comparable as a cardiovascular-focused CRO serving pharma/biotech sponsors, though predominantly clinical-phase.
Direct peers
- Physiogenex: Sister preclinical CRO sharing the same CEO (Dr. Thierry Sulpice), facilities in Escalquens, and a cardiometabolic focus. Directly comparable as a similarly sized French preclinical CRO serving pharma/biotech with metabolic disease models.
- Pelvipharm: French preclinical CRO specializing in vascular and women's health pharmacology, where Cardiomedex's Director of Business Development (Dr. Rana Assaly) was previously COO. Closely comparable in size, therapeutic niche, and French preclinical CRO model.
Emerging players
- Reaction Biology: Preclinical CRO offering cardiovascular safety and efficacy profiling services. Comparable emerging player in specialized preclinical cardiovascular pharmacology for biotech sponsors.
- Bienta (Enamine contract research): Preclinical CRO with in vivo pharmacology capabilities across metabolic and cardiovascular indications. Comparable as a smaller, emerging preclinical CRO competing for European biotech preclinical contracts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
cardiomedex social profiles
Digital presencecardiomedex compliance and trust
Trust signalCompliance2 records
cardiomedex financial estimates
Financial estimateRevenue estimate
Valuation estimate
cardiomedex leadership team
Management profileNumber of profiles
cardiomedex subsidiaries and ownership
Company hierarchySubsidiaries1 record
cardiomedex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
cardiomedex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about cardiomedex
What does cardiomedex do?
Cardiomedex is a preclinical contract research organization (CRO) that provides fee-for-service preclinical studies for pharmaceutical and biotechnology companies developing cardiovascular and cardiometabolic drugs. Its offering combines three service lines: in vivo animal models (HFpEF, HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, NASH, diabetic nephropathy), in vivo functional exploration (echocardiography, telemetry, hemodynamic measurements), and ex vivo/in vitro assays (vascular reactivity, Langendorff perfused heart), supplemented by drug development consulting.
Is cardiomedex a public or private company?
cardiomedex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was cardiomedex founded?
cardiomedex was founded in 2011. It employs 1 to 10 people.
Where is cardiomedex based?
cardiomedex is headquartered in Escalquens, France, in the Europe region.
How does cardiomedex make money?
Two revenue lines are on record. Preclinical CRO Services are the primary driver. The others are consulting Services.
Who are cardiomedex's main competitors?
Broad incumbents on record are Eurofins Scientific, Crown Bioscience, WuXi AppTec, Charles River Laboratories, Inotiv and Medpace. Direct peers are Physiogenex and Pelvipharm. Emerging players are Reaction Biology and Bienta (Enamine contract research).
Does cardiomedex have an API?
No public API is recorded for cardiomedex.
What industry is cardiomedex in?
cardiomedex's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 5417.